GlassScriptPhysician profile
David D Ufberg
NPI 1588696959
$1,776.21
in general payments reported to CMS, 2019-2025
22 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $16.02 · 2021: $255 · 2022: $405 · 2023: $299 · 2024: $381 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.08 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Aspira Women'S Health INC | $255.25 | 2021 | |
| Coopersurgical, INC. | $179.41 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $144.23 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $121.20 | 2019-2022 | |
| Caldera Medical, INC | $101.40 | 2024 | Desara |
| Evofem Biosciences, INC. | $95.26 | 2022-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $74.06 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $62.07 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $49.07 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $44.47 | 2024 | Myfembree |
| Sage Therapeutics, LLC | $42.02 | 2025 | Zurzuvae |
| Pfizer INC. | $40.59 | 2024 | |
| Supernus Pharmaceuticals, INC. | $39.82 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $36.54 | 2020-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.00 | 2025 | |
| Mayne Pharma Commercial LLC | $28.57 | 2022-2025 | |
| Myovant Sciences INC. | $22.87 | 2022 | |
| Ibsa Pharma INC. | $21.10 | 2023 | Tirosint, Licart |
| Roche Diagnostics Corporation | $19.36 | 2019 | |
| Meditrina | $17.08 | 2022 | |
| Merck Sharp & Dohme LLC | $15.76 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ufberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.